← back to search

Yuzhen Li

Harbin Medical University · CN
Area of research
Immunology · Rheumatology
Research interest
Research interests include Psoriasis: Treatment and Pathogenesis, Spondyloarthritis Studies and Treatments, Cytokine Signaling Pathways and Interactions, and Dermatology and Skin Diseases.
h-index
18
citations
917
works
64
NIH funding
primary concept
email

Recent publications

Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase Ib, randomized, double-blind, placebo-controlled study
British Journal of Dermatology 2025cited by 3position: middledoi
Current status of generalized pustular psoriasis: Findings from a multicenter hospital-based survey of 127 Chinese patients
Chinese Medical Journal 2025cited by 3position: middledoi
Efficacy and safety of supramolecular salicylic acid in the treatment of papulopustular rosacea: a multicentre randomized, double-blind, placebo-controlled superiority study
Clinical and Experimental Dermatology 2025cited by 1position: middledoi
Sequential requirements for distinct Polθ domains during theta-mediated end joining
Molecular Cell 2024cited by 21position: middledoi
SPRR1B is Related to the Immune Microenvironment and Can Be Used as a Biomarker for the Diagnosis of Psoriasis
International Journal of General Medicine 2024cited by 5position: lastdoi
Application of injectable hydrogels in cancer immunotherapy
Frontiers in Bioengineering and Biotechnology 2023cited by 29position: lastdoi
Hemoporfin-mediated photodynamic therapy for the treatment of port-wine stain: A multicenter, retrospective study
Photodiagnosis and Photodynamic Therapy 2023cited by 27position: middledoi
Increase of ISG15 in psoriasis lesions and its promotion of keratinocyte proliferation via the Hif‐1α signalling pathway
Experimental Dermatology 2023cited by 6position: lastdoi
Clinical practice Guidelines for 5-Aminolevulinic acid photodynamic therapy for acne vulgaris in China
Photodiagnosis and Photodynamic Therapy 2022cited by 52position: middledoi
A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis
International Immunopharmacology 2022cited by 11position: middledoi
A Randomized, Double-Blind Phase III Study to Demonstrate the Clinical Similarity of Biosimilar SCT630 to Reference Adalimumab in Chinese Patients with Moderate to Severe Plaque Psoriasis
SSRN Electronic Journal 2022cited by 2position: middledoi
Bacterial Outer Membrane‐Coated Mesoporous Silica Nanoparticles for Targeted Delivery of Antibiotic Rifampicin against Gram‐Negative Bacterial Infection In Vivo
Advanced Functional Materials 2021cited by 144position: middledoi
Fight bacteria with bacteria: Bacterial membrane vesicles as vaccines and delivery nanocarriers against bacterial infections
Nanomedicine Nanotechnology Biology and Medicine 2021cited by 41position: middledoi
A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis
Chinese Medical Journal 2020cited by 36position: middledoi
Tazarotene/Betamethasone Dipropionate Cream in Patients with Plaque Psoriasis: Results of a Prospective, Multicenter, Observational Study
Dermatology 2020cited by 7position: middledoi
Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial
Archives of Dermatological Research 2019cited by 20position: middledoi
MiR-876-5p suppresses cell proliferation by targeting Angiopoietin-1 in the psoriasis
Biomedicine & Pharmacotherapy 2018cited by 28position: lastdoi
Associations between STAT Gene Polymorphisms and Psoriasis in Northeastern China
Dermatology 2017cited by 9position: middledoi
Low-dose UVB irradiation prevents MMP2-induced skin hyperplasia by inhibiting inflammation and ROS
Oncology Reports 2015cited by 20position: middledoi
Role of the complement anaphylatoxin C5a-receptor pathway in atopic dermatitis in mice
Molecular Medicine Reports 2015cited by 14position: lastdoi
Study on susceptibility genes of psoriasis
Int J Genet 2015cited by 0position: middledoi
High prevalence of cardiovascular risk factors in patients with moderate or severe psoriasis in northern China
Archives of Dermatological Research 2014cited by 32position: middledoi
A large-scale screen for coding variants predisposing to psoriasis
Nature Genetics 2013cited by 218position: middledoi
Exploration and analysis of Humanistic Care for Patients with Psoriasis
Zhongguo yixue lunlixue 2013cited by 0position: first
Expression of lymphotoxin-β and its receptor in the skin of a mouse model of allergic contact dermatitis
Chinese Journal of Dermatology 2012cited by 0position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Qianjin Lu · Jiangsu University4 papers (2020–2025)Qing Sun · Guangzhou University of Chinese Medicine3 papers (2019–2022)Bingxue Bai · Harbin Medical University3 papers (2014–2015)Xian Jiang · Sichuan University3 papers (2022–2025)Hongzhong Jin · Union Hospital3 papers (2019–2022)Juan Tao · Shanghai Tenth People's Hospital3 papers (2022–2025)Xing‐Hua Gao · Sun Yat-sen University Cancer Center3 papers (2019–2025)Furen Zhang · Shandong University3 papers (2020–2022)Jun Gu · The First Affiliated Hospital, Sun Yat-sen University3 papers (2019–2022) · 3 papers (2020–2022)Lin Dang · Harbin Medical University3 papers (2012–2015)Gang Wang · Wuhan Institute of Technology3 papers (2019–2022)Yu Chen · Shandong University3 papers (2019–2022)Shuping Guo · Shanxi Medical University2 papers (2022–2022)Peiyan Yuan · Sun Yat-sen University2 papers (2021–2021)Zhiqiang Song · Second Military Medical University2 papers (2022–2022)Lei He · Harbin Medical University2 papers (2015–2015)Shuang Wu · Nantong University2 papers (2021–2021)Jing Zhou · Harbin Medical University2 papers (2015–2017)Siyu Hao · Harbin Medical University2 papers (2018–2024)